Elite Pharmaceuticals, Inc.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Elite Pharmaceuticals reports stellar Q1 results and eyes growth opportunities

Elite Pharmaceuticals delivered robust Q1 2025 results, showcasing significant revenue and income growth, improved cash flow, and strong financial health. Strategic investments and operational focus contributed to the company's success.
With a solid cash position, working capital, and proactive growth initiatives, Elite Pharmaceuticals is well-positioned to capitalize on market opportunities, drive innovation, and maintain compliance and operational excellence.
While challenges in sustaining growth and navigating regulatory requirements exist, Elite Pharmaceuticals' focus on strategic planning, financial discipline, and market expansion presents promising opportunities for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elite Pharmaceuticals, Inc. engages in the provision of development and manufacture of pharmacological abuse-deterrent opioid products. It operates through the Abbreviated New Drug Applications and New Drug Applications segments. The ANDA segment includes generic pharmaceuticals. The NDA segment is composed of branded pharmaceuticals. The company was founded on October 1, 1997 and is headquartered in Northvale, NJ.

Elite Pharmaceuticals, Inc. (ELTP) CEO Nasrat Hakim on Q3 2021 Results - Earnings Call Transcript

NORTHVALE, NJ / ACCESSWIRE / January 5, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, is pleased to announce the hiring of Dr. Jason M. LePree as Vice President of Scientific Affairs to oversee all technical facets of Elite's pharmaceutical and product development programs.

Elite Pharmaceuticals, Inc. Appoints Dr. Jason M. LePree as Vice President of Scientific Affairs

News for Elite Pharmaceuticals, Inc. Stock (ELTP)